Skip to main content

Ongoing support to help start and stay on PLUVICTO treatment

Once you and your health care provider decide to begin PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan), Novartis Patient Support is here to help.
 

We can help you:
Documents icon

Navigate the insurance process

Your dedicated Novartis Patient Support team can work with your provider to help navigate insurance coverage for your medication

Financial support icon

Get financial support*

If you have private insurance, you could be eligible for Co-Pay Plus and pay as little as $25 for your PLUVICTO treatment

Question bubble icon

Answers to questions across the treatment journey

Speak to a live Novartis Patient Support agent about what to expect before, during, or after treatment

*Limitations apply. Valid only for those patients with commercial insurance. Not valid under Medicare, Medicaid, or any other federal or state program. Offer subject to a maximum benefit per course of treatment. Novartis reserves the right to rescind, revoke, or amend this program without notice. See complete Terms and Conditions in the enrollment forms for details.

Important Safety Information

What is the most important information I should know about PLUVICTO?

Use of PLUVICTO involves exposure to radioactivity. Long-term, accruing radiation exposure is associated with an increased risk for cancer...
 

Approved Use

What is PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan)?

PLUVICTO is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen­–­positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that...

Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USE